Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
QR-1123 Investigational New Drug application active for autosomal dominant re
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim
… 2/3 trial of ultevursen (QR-421a), for USH2A -mediated Usher syndrome and retinitis pigmentosa Cash runway into 2025 … 2/3 trial of ultevursen (QR-421a), for USH2A -mediated Usher syndrome and retinitis pigmentosa. ProQR is … About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of combined deafness and …
… 2/3 trial of ultevursen (QR-421a), for USH2A -mediated Usher syndrome and retinitis pigmentosa ProQR is accelerating … 2/3 trial of ultevursen (QR-421a), for USH2A -mediated Usher syndrome and retinitis pigmentosa. ProQR is … About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of combined deafness and …
… for LCA10 and ultevursen (QR-421a) for USH2A -mediated Usher syndrome and retinitis pigmentosa, the Company will … About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of combined deafness and blindness. People with Usher syndrome type 2a are usually born with hearing loss and …
… Focus the ultevursen (QR-421a) program for USH2A -mediated Usher syndrome and retinitis pigmentosa on a single Phase 2/3 … About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of combined deafness and blindness. People with Usher syndrome type 2a are usually born with hearing loss and …